Klk4 induces anti-tumor effects in human xenograft mouse models of orthotopic and metastatic prostate cancer

6Citations
Citations of this article
11Readers
Mendeley users who have this article in their library.

Abstract

Recent reports have suggested the role of kallikrein-related peptidase 4 (KLK4) to be that of remodeling the tumor microenvironment in many cancers, including prostate cancer. Notably, these studies have suggested a pro-tumorigenic role for KLK4, especially in prostate cancer. However, these have been primarily in vitro studies, with limited in vivo studies performed to date. Herein, we employed an orthotopic inoculation xenograft model to mimic the growth of primary tumors, and an intracardiac injection to induce metastatic dissemination to determine the in vivo tumorigenic effects of KLK4 overexpressed in PC3 prostate cancer cells. Notably, we found that these KLK4-expressing cells gave rise to smaller localized tumors and decreased metastases than the parent PC-3 cells. To our knowledge, this is the first report of an anti-tumorigenic effect of KLK4, particularly in prostate cancer. These findings also provide a cautionary tale of the need for in vivo analyses to substantiate in vitro experimental data.

Cite

CITATION STYLE

APA

Tse, B. W. C., Kryza, T., Yeh, M. C., Dong, Y., Sokolowski, K. A., Walpole, C., … Clements, J. A. (2020). Klk4 induces anti-tumor effects in human xenograft mouse models of orthotopic and metastatic prostate cancer. Cancers, 12(12), 1–15. https://doi.org/10.3390/cancers12123501

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free